Jason H. Peragallo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jason H. Peragallo has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
Nancy J. Newman
Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia; Department of Neurology, Emory University School of Medicine, Atlanta, Georgia; Department of Neurological Surgery, Emory University School of Medicine, Atlanta, Georgia
6 shared publicationsValérie Biousse
Department of Ophthalmology, Emory University School of Medicine, Atlanta, Georgia; Department of Neurology, Emory University School of Medicine, Atlanta, Georgia
6 shared publicationsBeau B. Bruce
From the Department of Ophthalmology (V.B., M.Y.L., B.B.B., N.J.N.), Emory University School of Medicine, Atlanta, Georgia, USA; Department of Neurology (V.B., B.B.B., N.J.N.), Emory University School of Medicine, Atlanta, Georgia, USA; Rollins School of Public Health (B.B.B.), Emory University School of Medicine, Atlanta, Georgia, USA
5 shared publicationsAmy K. Hutchinson
Departments of Ophthalmology
2 shared publications- Bruno Passebon Soares
Department of Radiology, Stanford University School of Medicine, Stanford, United States
2 shared publications Caroline Vasseneix
Department of Ophthalmology, Emory University School of Medicine, Atlanta, USA
2 shared publications
Latest Publications
- 23 March 2026
- Published by Wolters Kluwer Health in International Ophthalmology Clinics
- Vol. 66 (2) , 63
Forward: Pediatric Neuro-Ophthalmology
- 23 March 2026
- Published by Wolters Kluwer Health in International Ophthalmology Clinics
- Vol. 66 (2) , 63
Forward: Pediatric Neuro-Ophthalmology
- 4 March 2025
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
- Vol. 29 (2) , 104158
Etiologies underlying pediatric papilledema at a tertiary care children’s hospital
- 4 March 2025
- Published by Elsevier in Journal of American Association for Pediatric Ophthalmology and Strabismus
- Vol. 29 (2) , 104158
Etiologies underlying pediatric papilledema at a tertiary care children’s hospital
- 6 January 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 262, 186-191
Outcomes of Strabismus Surgery Following Teprotumumab Therapy
- 6 January 2024
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 262, 186-191
Outcomes of Strabismus Surgery Following Teprotumumab Therapy
- Open Access
- 4 November 2023
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 261, 199-207
Application of a Deep Learning System to Detect Papilledema on Nonmydriatic Ocular Fundus Photographs in an Emergency Department
- 4 November 2023
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 261, 199-207
Open AccessApplication of a Deep Learning System to Detect Papilledema on Nonmydriatic Ocular Fundus Photographs in an Emergency Department
- Open Access
- 30 August 2021
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 154 (3) , 365-373
Vision-related quality-of-life in pediatric primary brain tumor patients
Purpose Brain tumors are the leading cause of death from childhood cancer. Although overall survival has improved due to earlier detection, better therapies, and improved surveillance, visual dysfunction and impaired vision-related quality-of-life (VR-QOL) are often unrecognized in children. This project investigated VR-QOL in pediatric brain tumor patients. Methods We evaluated visual impairment and quality-of-life (QOL) in a quality improvement project at one tertiary care center. Patients ≤ 18, greater than 6 months from diagnosis of brain tumor, excluding intrinsic anterior visual pathway tumors, underwent standardized neuro-ophthalmologic examination. Health-related QOL (HR-QOL) (PedsQL Brain Tumor Module) and VR-QOL questionnaires [CVFQ (Children’s Visual Function Questionnaire) in children < 8, and EYE-Q in children 8–18] were obtained from patients and parents. Results Among 77 patients, craniopharyngiomas (n = 16, 21%) and astrocytomas (n = 15, 20%) were the most common tumors. Among 44/77 (57%) visually impaired children, 7 (16%) were legally blind. Eye-Q median score was 3.40 (interquartile range 3.00–3.75), worse than average scores for normal children. Eye-Q score decreased 0.12 with every 0.1 increase in logMAR visual acuity (p < 0.001). Patients who were legally blind had a significantly lower Eye-Q score than those who were not [0.70 vs. 3.44 (p < 0.001)]. Cognitive HR-QOL scores decreased 1.3 for every 0.1 increase in logMAR visual acuity (p = 0.02). Conclusions Pediatric brain tumor patients’ vision, HR-QOL, and VR-QOL were often severely affected even when tumors were considered cured. Visual acuity and legal blindness correlated with VR-QOL. Systematic neuro-ophthalmologic examinations in pediatric primary brain tumor patients are necessary to facilitate early preventative and corrective ophthalmologic interventions.
- 30 August 2021
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 154 (3) , 365-373
Open AccessVision-related quality-of-life in pediatric primary brain tumor patients
Purpose Brain tumors are the leading cause of death from childhood cancer. Although overall survival has improved due to earlier detection, better therapies, and improved surveillance, visual dysfunction and impaired vision-related quality-of-life (VR-QOL) are often unrecognized in children. This project investigated VR-QOL in pediatric brain tumor patients. Methods We evaluated visual impairment and quality-of-life (QOL) in a quality improvement project at one tertiary care center. Patients ≤ 18, greater than 6 months from diagnosis of brain tumor, excluding intrinsic anterior visual pathway tumors, underwent standardized neuro-ophthalmologic examination. Health-related QOL (HR-QOL) (PedsQL Brain Tumor Module) and VR-QOL questionnaires [CVFQ (Children’s Visual Function Questionnaire) in children < 8, and EYE-Q in children 8–18] were obtained from patients and parents. Results Among 77 patients, craniopharyngiomas (n = 16, 21%) and astrocytomas (n = 15, 20%) were the most common tumors. Among 44/77 (57%) visually impaired children, 7 (16%) were legally blind. Eye-Q median score was 3.40 (interquartile range 3.00–3.75), worse than average scores for normal children. Eye-Q score decreased 0.12 with every 0.1 increase in logMAR visual acuity (p < 0.001). Patients who were legally blind had a significantly lower Eye-Q score than those who were not [0.70 vs. 3.44 (p < 0.001)]. Cognitive HR-QOL scores decreased 1.3 for every 0.1 increase in logMAR visual acuity (p = 0.02). Conclusions Pediatric brain tumor patients’ vision, HR-QOL, and VR-QOL were often severely affected even when tumors were considered cured. Visual acuity and legal blindness correlated with VR-QOL. Systematic neuro-ophthalmologic examinations in pediatric primary brain tumor patients are necessary to facilitate early preventative and corrective ophthalmologic interventions.
- 1 January 2020
- Published by HMP Communications, LLC in Consultant
- Vol. 60 (3)
Autoimmune Hemolytic Anemia Associated With Intracranial Hypertension in an 8-Year-Old Boy
- 1 January 2020
- Published by HMP Communications, LLC in Consultant
- Vol. 60 (3)
Autoimmune Hemolytic Anemia Associated With Intracranial Hypertension in an 8-Year-Old Boy
- 1 November 2019
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 30 (6) , 418-425
Update on pediatric optic neuritis
To summarize recent developments in the classification, investigation and management of pediatric optic neuritis (PON). A recent surge in interest surrounding antibodies to myelin oligodendrocyte glycoprotein antibody (MOG-Ab) has instigated a paradigm shift in our assessment of children with PON. This serological marker is associated with a broad spectrum of demyelinating syndromes that are clinically and radiologically distinct from multiple sclerosis (MS) and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder (AQP4+NMOSD). Optic neuritis is the most common presenting phenotype of MOG-Ab positive-associated disease (MOG+AD). MOG-Ab seropositivity is much more common in the pediatric population and it predicts a better prognosis than MS or AQP4+NMOSD, except in the subset that exhibit a recurrent phenotype. A better grasp of MOG+AD features and its natural history has facilitated more accurate risk stratification of children after a presenting episode of PON. Consequently, the initial investigation of PON has broadened to include serology, along with neuroimaging and cerebrospinal fluid analysis. Acute treatment of PON and chronic immunotherapy is also becoming better tailored to the suspected or confirmed diagnoses of MS, AQP4+NMOSD and MOG+AD.
- 1 November 2019
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 30 (6) , 418-425
Update on pediatric optic neuritis
To summarize recent developments in the classification, investigation and management of pediatric optic neuritis (PON). A recent surge in interest surrounding antibodies to myelin oligodendrocyte glycoprotein antibody (MOG-Ab) has instigated a paradigm shift in our assessment of children with PON. This serological marker is associated with a broad spectrum of demyelinating syndromes that are clinically and radiologically distinct from multiple sclerosis (MS) and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder (AQP4+NMOSD). Optic neuritis is the most common presenting phenotype of MOG-Ab positive-associated disease (MOG+AD). MOG-Ab seropositivity is much more common in the pediatric population and it predicts a better prognosis than MS or AQP4+NMOSD, except in the subset that exhibit a recurrent phenotype. A better grasp of MOG+AD features and its natural history has facilitated more accurate risk stratification of children after a presenting episode of PON. Consequently, the initial investigation of PON has broadened to include serology, along with neuroimaging and cerebrospinal fluid analysis. Acute treatment of PON and chronic immunotherapy is also becoming better tailored to the suspected or confirmed diagnoses of MS, AQP4+NMOSD and MOG+AD.
- 14 March 2019
- Published by Taylor & Francis in Neuro-Ophthalmology
- Vol. 43 (6) , 371-374
Lack of Relationship between Central Corneal Thickness and Papilloedema in Idiopathic Intracranial Hypertension
Translaminar pressure gradient abnormalities have been implicated in the pathogenesis and progression of glaucoma. A “reversed” translaminar pressure gradient may be related to papilloedema severity in idiopathic intracranial hypertension. Central corneal thickness is related to intraocular pressure measurements and, by extension, to translaminar pressure gradients. We evaluated if central corneal thickness could be a marker of worse papilloedema due to altered translaminar pressure gradients in patients with idiopathic intracranial hypertension. We found that central corneal thickness was not related to the severity of papilloedema in idiopathic intracranial hypertension.
- 14 March 2019
- Published by Taylor & Francis in Neuro-Ophthalmology
- Vol. 43 (6) , 371-374
Lack of Relationship between Central Corneal Thickness and Papilloedema in Idiopathic Intracranial Hypertension
Translaminar pressure gradient abnormalities have been implicated in the pathogenesis and progression of glaucoma. A “reversed” translaminar pressure gradient may be related to papilloedema severity in idiopathic intracranial hypertension. Central corneal thickness is related to intraocular pressure measurements and, by extension, to translaminar pressure gradients. We evaluated if central corneal thickness could be a marker of worse papilloedema due to altered translaminar pressure gradients in patients with idiopathic intracranial hypertension. We found that central corneal thickness was not related to the severity of papilloedema in idiopathic intracranial hypertension.
- 18 August 2017
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 39 (1) , 99-102
Retinopathy and optic atrophy: Expanding the phenotypic spectrum of pathogenic variants in the AARS2 gene
Background: Optic atrophy may be the sequela of optic nerve injury due to any insult, including isolated and syndromic genetic diseases. Alanyl-tRNA synthetase 2 (AARS2) pathogenic variants have been reported to cause leukodystrophy with ovarian failure, and cardiomyopathy (#615889) as well as combined oxidative phosphorylation deficiency-8 (#614096). We report a young child who presented with decreased vision due to optic atrophy and was found to harbor missense variants in the AARS2 gene expanding the phenotypic expression of the AARS2 gene.Materials and Methods: Single observational case report with genetic testing, laboratory testing, neurologic and ophthalmic clinical examinations, and neuroimaging performed at a tertiary academic medical center.Results: An 18-month old Korean boy was noted to have a progressive decline in visual function. The physical exam revealed bilateral optic atrophy, peripheral retinal bone spicule pigmentation, and absent patellar reflexes. Electromyography was consistent with demyelinating polyneuropathy. Magnetic resonance imaging (MRI) of the brain and spine showed cerebellar and supratentorial white matter multifocal changes with areas of restricted diffusion, and dorsal column signal abnormalities. Whole exome sequencing revealed two missense variants in the AARS2 gene [c.1519G>C (p.V507L) and c.2165G>A (p.R722Q)], found to be in trans on parental testing.Conclusions: Missense variants in the AARS2 gene are the likely cause of the retinopathy and optic atrophy in this patient. This finding expands the phenotypic spectrum of the AARS2 gene.
- 18 August 2017
- Published by Taylor & Francis in Ophthalmic Genetics
- Vol. 39 (1) , 99-102
Retinopathy and optic atrophy: Expanding the phenotypic spectrum of pathogenic variants in the AARS2 gene
Background: Optic atrophy may be the sequela of optic nerve injury due to any insult, including isolated and syndromic genetic diseases. Alanyl-tRNA synthetase 2 (AARS2) pathogenic variants have been reported to cause leukodystrophy with ovarian failure, and cardiomyopathy (#615889) as well as combined oxidative phosphorylation deficiency-8 (#614096). We report a young child who presented with decreased vision due to optic atrophy and was found to harbor missense variants in the AARS2 gene expanding the phenotypic expression of the AARS2 gene.Materials and Methods: Single observational case report with genetic testing, laboratory testing, neurologic and ophthalmic clinical examinations, and neuroimaging performed at a tertiary academic medical center.Results: An 18-month old Korean boy was noted to have a progressive decline in visual function. The physical exam revealed bilateral optic atrophy, peripheral retinal bone spicule pigmentation, and absent patellar reflexes. Electromyography was consistent with demyelinating polyneuropathy. Magnetic resonance imaging (MRI) of the brain and spine showed cerebellar and supratentorial white matter multifocal changes with areas of restricted diffusion, and dorsal column signal abnormalities. Whole exome sequencing revealed two missense variants in the AARS2 gene [c.1519G>C (p.V507L) and c.2165G>A (p.R722Q)], found to be in trans on parental testing.Conclusions: Missense variants in the AARS2 gene are the likely cause of the retinopathy and optic atrophy in this patient. This finding expands the phenotypic spectrum of the AARS2 gene.
- 1 May 2017
- Published by Elsevier in Seminars in Pediatric Neurology
- Vol. 24 (2) , 116-121
Pediatric Myasthenia Gravis
- 1 May 2017
- Published by Elsevier in Seminars in Pediatric Neurology
- Vol. 24 (2) , 116-121
Pediatric Myasthenia Gravis